desktop bg

    ASCO 2026

    Presentations Supported by Bayer

    May 29- June 2, 2026

    Agenda of oral and poster presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting 


    Please see below to download a PDF for each presentation and view a video (where applicable). Access for each publication will be available after the congress presentation.

    Please select a compound to navigate to all related publications.

    DAROLUTAMIDE

    desktop listing bg

    Prostate-specific antigen outcomes of darolutamide and androgen deprivation therapy in patient subgroups by age, comorbidities, and concomitant medications: ARANOTE post hoc analyses

    Date/Time:
    May 31, 2026 | 9:00 AM – 12:00 PM CDT

    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile

    Type:
    Poster Session 

    Presenting Author:
    Fred Saad

    Abstract Number:
    5103

    desktop listing bg

    Major adverse cardiovascular events in androgen receptor signaling inhibitor–treated patients with metastatic castration-sensitive prostate cancer

    Date/Time:
    May 31, 2026 | 9:00 AM – 12:00 PM CDT

    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile

    Type:
    Poster Session

    Presenting Author:
    Linden Huhmann

    Abstract Number:
    5107

    desktop listing bg

    Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology

    Date/Time:
    May 30, 2026 | 4:24 PM  – 4:36 PM CDT 

    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile

    Type:
    Oral Abstract Session 

    Presenting Author:
    Alicia K. Morgans

    Abstract Number:
    5005

    desktop listing bg

    A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy–naïve recurrent and/or metastatic androgen receptor (AR)–positive salivary gland cancer (ETCTN 10553)

    Date/Time:
    June 1, 2026 | 8:48 AM  – 9:00 AM CDT  

    Session:
    Head and Neck Cancer

    Type:
    Clinical Science Symposium 

    Presenting Author:
    Alan Loh Ho

    Abstract Number:
    6012

    desktop listing bg

    Comeback from long-course ADT with relugolix (rel) and darolutamide (daro) in hormone-sensitive prostate cancer (PC) (CLEARED)

    Date/Time:
    May 31, 2026 | 9:00 AM – 12:00 PM CDT

    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile

    Type:
    Poster Session 

    Presenting Author:
    Atish Choudhury

    Abstract Number:
    5083

    desktop listing bg

    Classification tree phenotypes for early treatment-limiting toxicity after androgen receptor pathway inhibitor initiation in metastatic hormone-sensitive prostate cancer from the IRONMAN registry

    Date/Time:
    May 31, 2026 | 9:00 AM  – 12:00 PM CDT 

    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile

    Type:
    Poster Session 

    Presenting Author:
    Alexandra Larkin

    Abstract Number:
    5095

    desktop listing bg 1070*420

    Real-world cost effectiveness of androgen receptor pathway inhibitors for metastatic hormone sensitive prostate cancer: An economic evaluation utilizing data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN)

    Date/Time:
    June 1, 2026 | 9:00 AM  – 12:00 PM CDT  

    Session:
    Quality Care/Health Services Research

    Type:
    Poster Session 

    Presenting Author:
    Rebecca Green

    Abstract Number:
    11164

    LAROTRECTINIB

    desktop listing bg 1070*420

    Efficacy and safety of larotrectinib in patients with non-primary central nervous system
    TRK
    fusion cancer: An updated analysis

    Date/Time:
    May 30, 2026 | 1:30 PM – 4:30 PM CDT 

    Session:
    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

    Type:
    Poster Session

    Presenting Author:
    Alexander E. Drilon

    Abstract Number:
    3145

    desktop listing bg 1070*420

    Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis

    Date/Time:
    May 31, 2026 | 9:00 AM – 12:00 PM CDT 

    Session:
    Lung Cancer—Non-Small Cell Metastatic

    Type:
    Poster Session

    Presenting Author:
    Jessica Lin

    Abstract Number:
    8618

    desktop listing bg 1070*420

    Precision oncology in practice: Real-world multicenter experience with larotrectinib in pediatric extracranial NTRK fusion–positive tumors

    Date/Time:
    June 1, 2026 | 1:30 PM - 4:30 PM CTD

    Session:
    Pediatric Oncology

    Type:
    Poster

    Presenting Author:
    Rejin Kebudi

    Abstract Number:
    10036

    RADIUM-223

    desktop listing bg 1070*420

    ETCTN 10302: A randomized phase II trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer

    Date/Time:
    May 30, 2026 | 1:30 PM – 4:30 PM CDT

    Session:
    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

    Type:
    Poster Session 

    Presenting Author:
    Jyoti Malhotra

    Abstract Number:
    3096

    desktop listing bg 1070*450

    A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801)

    Date/Time:
    May 29, 2026 | 2:45 PM – 2:57 PM CDT 

    Session:
    Genitourinary Cancer—Kidney and Bladder

    Type:
    Oral Abstract Session 

    Presenting Author:
    Rana R. McKay

    Abstract Number:
    4500

    desktop listing bg 1070*420

    Cell-free DNA nucleosome and genomic signatures as predictors of outcomes with radium-223 in metastatic castration-resistant prostate cancer

    Date/Time:
    May 31, 2026 | 9:00 AM – 12:00 PM CDT 

    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile

    Type:
    Poster Session

    Presenting Author:
    David Chen

    Abstract Number:
    5039

    desktop listing bg 1070*420

    Quality of life analysis from a multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 versus radium-223 in metastatic castration-resistant prostate cancer with bone metastases (COMRADE)

    Date/Time:
    May 31, 2026 | 9:00 AM – 12:00 PM CDT 

    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile

    Type:
    Poster Session

    Presenting Author:
    Rana R. McKay

    Abstract Number:
    5040

    REGORAFENIB

    desktop listing bg 1070*420

    Evaluation of the combination of regorafenib + avelumab in patients with HPV-associated cancer: The phase II REGOMUNE study

    Date/Time:
    May 30, 2026 | 8:42 AM – 8:48 AM CDT  

    Session:
    Developmental Therapeutics—Immunotherapy

    Type:
    Rapid Oral Abstract Session 

    Presenting Author:
    Sophie Cousin

    Abstract Number:
    2517

    SEVABERTINIB

    desktop listing bg 1070*420

    SOHO-01: Updated safety and efficacy of sevabertinib in patients with advanced
    HER2
    -mutant non-small cell lung cancer (NSCLC)

    Date/Time:
    May 31, 2026 | 9:00 AM – 12:00 PM CDT 

    Session:
    Lung Cancer—Non-Small Cell Metastatic

    Type:
    Poster Session 

    Presenting Author:
    Herbert H. Loong

    Abstract Number:
    8862

    Footer desktop bg

    Terms and Conditions

    Privacy Policy

    Medical Information

    The compendium provided by Bayer is a compilation of Bayer sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from The American Society of Clinical Oncology (ASCO) and from the authors. The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.

    Reused with permission. © 2026 The American Society of Clinical Oncology (ASCO). All rights reserved.

    For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR

    © 2026 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981 USA. 5/26

    MA-M_DAR-US-0402-1
    MA-M_DAR-US-0403-1